BMS-345541 hydrochloride: Selective IKK/NF-κB Pathway Inhibitor for Inflammation & Cancer Research

Executive Summary: BMS-345541 hydrochloride is a potent, selective inhibitor of IκB kinase isoforms IKK-1 and IKK-2 with IC₅₀ values of 4 μM and 0.3 μM, respectively, blocking stimulus-induced NF-κB activation and downstream pro-inflammatory cytokine production in vitro and in vivo (Zhao et al. 2025). The compound binds an allosteric site, sparing unrelated kinases and preserving off-pathway signaling. In T-cell acute lymphoblastic leukemia (T-ALL) models, BMS-345541 hydrochloride induces G2/M cell cycle arrest and apoptosis, countering chemoresistance. It is highly soluble in water (≥60 mg/mL), orally bioavailable (100% in animal models), and stable when stored at -20°C for months (APExBIO). The product is distributed by APExBIO and is widely used for mechanistic and translational research on NF-κB-driven pathology.

Biological Rationale

The NF-κB signaling pathway orchestrates cellular responses to inflammation, stress, and immune triggers. IκB kinases (IKK-1/IKK-2) regulate NF-κB activation via IκB phosphorylation and degradation, enabling nuclear translocation of NF-κB and transcription of pro-inflammatory cytokines (e.g., TNFα, IL-1β, IL-6, IL-8) (Zhao et al. 2025). Excessive or chronic NF-κB activation underpins many diseases, including autoimmune disorders, tracheal in-stent restenosis, and hematologic malignancies. Selective inhibition of IKK can uncouple inflammatory signaling from homeostatic processes, facilitating targeted research and therapeutic exploration. BMS-345541 hydrochloride offers high specificity for IKK-1/2, providing a precise tool for dissecting NF-κB-mediated responses in vitro and in vivo.

Mechanism of Action of BMS-345541 hydrochloride

BMS-345541 hydrochloride is a selective, allosteric inhibitor of IκB kinases (APExBIO). It binds to a unique allosteric site on the IKK complex, distinct from the ATP-binding pocket, conferring robust selectivity. IC₅₀ values for IKK-1 and IKK-2 inhibition are 4 μM and 0.3 μM, respectively, under cell-free kinase assay conditions (pH 7.4, 25°C). This selectivity is validated by the lack of inhibitory activity against other serine/threonine or tyrosine kinases at concentrations up to 100 μM. Upon binding, BMS-345541 hydrochloride prevents stimulus-induced phosphorylation and degradation of IκBα, thereby blocking NF-κB nuclear translocation and transcriptional activation of downstream cytokines. The inhibitor does not impact unrelated signaling pathways such as MAPK or JAK/STAT, as shown in cellular profiling studies (Practical Solutions for BMS-345541 hydrochloride).

Evidence & Benchmarks

• BMS-345541 hydrochloride exhibits IKK-2 inhibition with IC₅₀ = 0.3 μM and IKK-1 inhibition with IC₅₀ = 4 μM in enzymatic assays (APExBIO).
• The compound fails to inhibit unrelated kinases (e.g., MAPK, JAK) at ≤100 μM, confirming high selectivity (Cornerstone for Inflammation & Cancer Biology).
• In human cell lines, BMS-345541 hydrochloride blocks TNFα-, IL-1β-, IL-6-, and IL-8-induced NF-κB transcriptional activity (cell-based luciferase reporter assays, 37°C, 5% CO₂) (Zhao et al. 2025).
• Oral administration in animal models yields 100% bioavailability and suppresses TNFα levels in plasma (rat, 10 mg/kg, 2 hours post-dose) (APExBIO).
• Treatment of T-ALL cell lines induces G2/M arrest and apoptosis, suggesting reversal of chemoresistance (Pivotal Reagent for Pro-inflammatory Signaling).
• Water solubility is ≥60 mg/mL; the compound is insoluble in ethanol and DMSO at standard laboratory conditions (25°C) (APExBIO).
• Stock solutions remain stable for several months at -20°C, but working solutions should be used promptly (APExBIO).

This article extends previous reviews (Selective IKK Inhibitor for NF-κB Pathway Research) by providing updated stability data and integrating recent findings on apoptosis in T-ALL models. It also clarifies advanced workflow considerations not covered in scenario-driven guidance articles (Practical Solutions for BMS-345541 hydrochloride).

Applications, Limits & Misconceptions

Applications:

• Dissection of IKK/NF-κB signaling in inflammation research.
• In vivo and in vitro inhibition of pro-inflammatory cytokine production.
• Apoptosis induction and cell cycle arrest studies in T-ALL and other cancer models.
• Mechanistic evaluation of chemoresistance in hematologic malignancies.
• Tool for validating anti-inflammatory interventions in preclinical animal models.

Common Pitfalls or Misconceptions

• BMS-345541 hydrochloride does not inhibit non-IKK kinases; it is not a broad-spectrum kinase inhibitor.
• The compound is inactive in organic solvents such as ethanol and DMSO; only water-based systems ensure solubility and bioactivity.
• Long-term storage of working solutions at room temperature leads to rapid degradation; only stock solutions at -20°C are stable for months.
• NF-κB-independent inflammatory pathways (e.g., via NLRP3 inflammasome) are not affected by BMS-345541 hydrochloride.
• It is a research tool, not an approved therapeutic; in vivo efficacy does not imply clinical suitability.

Workflow Integration & Parameters

For in vitro work, BMS-345541 hydrochloride should be dissolved in sterile water to a concentration of ≥60 mg/mL. Aliquots should be stored at -20°C. For cell-based assays, typical working concentrations range from 0.1–10 μM, depending on cell type and endpoint. In animal studies, oral dosing (e.g., 10 mg/kg) achieves full bioavailability and rapid plasma TNFα suppression. Avoid using ethanol or DMSO as solvents to prevent precipitation and loss of activity. Before use, equilibrate stock solutions to room temperature and vortex to ensure homogeneity. Analytical verification of concentration, purity, and activity is recommended for each batch (Practical Solutions). For troubleshooting, see scenario guides on maximizing reproducibility and minimizing off-target effects (Scenario-Driven Guidance).

Conclusion & Outlook

BMS-345541 hydrochloride is a gold-standard, selective IKK/NF-κB pathway inhibitor that enables targeted research in inflammation and cancer biology. Its well-characterized mechanism, robust selectivity, and proven in vivo efficacy make it a preferred reagent for dissecting cytokine-driven pathology. Distributed by APExBIO, it is accessible to researchers globally. Future work may explore its integration with anti-angiogenic and anti-fibrotic strategies, as combinatorial approaches are increasingly relevant in complex disease models (Zhao et al. 2025).

For product specifications and ordering information, visit the BMS-345541 hydrochloride A3248 product page.